TS expression predicts postoperative recurrence in adenocarcinoma of the lung

Lung Cancer

Volumn 72, Issue 3, 2011, Pages 360-364

  Shimokawa, Hidehiko ^a   Uramoto, Hidetaka ^a   Onitsuka, Takamitsu ^a   Iwata, Teruo ^a   Nakagawa, Makoto ^a   Ono, Kenji ^a   Hanagiri, Takeshi ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Adenocarcinoma; DHFR; Lung cancer; Recurrence; Survival; TS

Indexed keywords

CARBOPLATIN; DIHYDROFOLATE REDUCTASE; GEMCITABINE; PACLITAXEL; THYMIDYLATE SYNTHASE; UFT;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE SECTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PNEUMONECTOMY; PROGNOSIS; TETRAHYDROFOLATE DEHYDROGENASE; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79955482651     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.08.024     Document Type: Article

References (29)

1. Minna J.D., Roth J.A., Gazdor A.F. Focus on lung cancer. Cancer Cell 2002, 1:49-52.
2. Hoffman P.C., Mauer A.M., Vokes E.E. Lung cancer. Lancet 2000, 355:479-485.
3. Asamura H., Goya T., Koshiishi Y., Sohara Y., Eguchi K., Mori M., et al. A Japanese lung cancer registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol 2008, 3:46-52.
4. Arriagada R., Auperin A., Burdett S., Higgins J.P., Johnson D.H., Le Chevalier T., et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010, 375:1267-1277.
5. Pignon J.P., Tribodet H., Scagliotti G.V., Douillard J.Y., Shepherd F.A., Stephens R.J., et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008, 26:3552-3559.
6. Nakagawa T., Otake Y., Yanagihara K., Miyahara R., Ishikawa S., Fukushima M., et al. Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC). Lung Cancer 2004, 43:145-149.
7. Yeh K.H., Shun C.T., Chen C.L., Lin J.T., Lee W.J., Lee P.H., et al. High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 1998, 82:1626-1631.
8. Harpole D.H., Moore M.B., Herndon J.E., Aloia T., D'Amico T.A., Sporn T., et al. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2001, 7:562-569.
9. Edler D., Kressner U., Ragnhammar P., Johnston P.G., Magnusson I., Glimelius B., et al. Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. Clin Cancer Res 2000, 6:488-492.
10. Scagliotti G., Hanna N., Fossella F., Sugarman K., Blatter J., Peterson P., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009, 14:253-263.
11. Yamashita T, Uramoto H, Onitsuka T, Ono K, Baba T, So T, et al. Association between lymphangiogenesis-/micrometastasis- and adhesion-related molecules in resected stage I NSCLC. Lung Cancer; in press. doi:10.1016/j.lungcan.2010.02.013.
12. Onitsuka T., Uramoto H., Nose N., Takenoyama M., Hanagiri T., Sugio K., et al. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer 2010, 68:198-203.
13. Onitsuka T., Uramoto H., Ono K., Takenoyama M., Hanagiri T., Oyama T., et al. Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status. J Thorac Oncol 2010, 5:591-596.
14. Toi M., Ikeda T., Akiyama F., Kurosumi M., Tsuda H., Sakamoto G., et al. Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy. Int J Oncol 2007, 31:899-906.
15. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest 1997, 111:1710-1717.
16. Christofori G. New signals from the invasive front. Nature 2006, 441:444-450.
17. Duffy M.J., van Dalen A., Haglund C., Hansson L., Holinski-Feder E., et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007, 43:1348-1360.
18. Rahman L., Voeller D., Rahman M., Lipkowitz S., Allegra C., Barrett J.C., et al. Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell 2004, 5:341-351.
19. Nakagawa T., Tanaka F., Otake Y., Yanagihara K., Miyahara R., Matsuoka K., et al. Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung. Lung Cancer 2002, 35:165-170.
20. Huang C., Liu D., Masuya D., Nakashima T., Kameyama K., Ishikawa S., et al. Clinical application of biological markers for treatments of resectable non-small-cell lung cancers. Br J Cancer 2005, 92:1231-1239.
21. Park J.H., Choi H., Kim Y.B., Kim Y.S., Sheen S.S., Choi J.H., et al. Serum angiopoietin-1 as a prognostic marker in resected early stage lung cancer. Lung Cancer 2009, 66:359-364.
22. Iwakiri S., Mino N., Takahashi T., Sonobe M., Nagai S., Okubo K., et al. Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer. Cancer 2009, 115:2580-2593.
23. Miyoshi T., Kondo K., Toba H., Yoshida M., Fujino H., Kenzaki K., et al. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer. Anticancer Res 2007, 27:2641-2648.
24. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
25. Hashimoto H., Ozeki Y., Sato M., Obara K., Matsutani N., Nakagishi Y., et al. Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung. Cancer 2006, 106:1595-1601.
26. Zheng Z., Li X., Schell M.J., Chen T., Boulware D., Robinson L., et al. Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer 2008, 112:2765-2773.
27. Ceppi P., Volante M., Saviozzi S., Rapa I., Novello S., Cambieri A., et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006, 107:1589-1596.
28. Ishihama H., Chida M., Araki O., Karube Y., Seki N., Tamura M., et al. Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung. Jpn J Clin Oncol 2009, 39:33-36.
29. Chang M.H., Ahn J.S., Lee J., Kim K.H., Park Y.H., Han J., et al. The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer. Lung Cancer 2010, 69:323-329.